Choosing the right inhaled medication device for COPD
Ray, S.' M.; Barger Stevens, A.R.
American Family Physician 88(10): 650; 652
2013
ISSN/ISBN: 1532-0650
PMID: 24364480
Accession: 052071847
PDF emailed within 1 workday: $29.90
Related References
Koehorst-ter Huurne, K.; Movig, K.; van der Valk, P.; van der Palen, J.; Brusse-Keizer, M. 2016: The influence of type of inhalation device on adherence of COPD patients to inhaled medication Expert Opinion on Drug Delivery 13(4): 469-475Koehorst-Ter Huurne, K.; Brusse-Keizer, M.; van der Valk, P.; Movig, K.; van der Palen, J.; Bode, C. 2018: Patients with underuse or overuse of inhaled corticosteroids have different perceptions and beliefs regarding COPD and inhaled medication Patient Preference and Adherence 12: 1777-1783
Duarte-de-Araújo, A.; Teixeira, P.; Figueiredo, M.; Hespanhol, V.; Correia-de-Sousa, J. 2017: Understanding patient adherence to inhaled medication: The social representations of COPD Revista Portuguesa de Pneumologia 23(6): 358-359
Capstick, T.G.D.; Hopkinson, N.S. 2021: Adapting Inhaled Medication Practice in COPD and Asthma to Avoid Funding the Tobacco Industry International Journal of Chronic Obstructive Pulmonary Disease 16: 2917-2923
Gregoriano, C.; Dieterle, T.; Breitenstein, A.-L.; Dürr, S.; Baum, A.; Maier, S.; Arnet, I.; Hersberger, K.E.; Leuppi, J.ör.D. 2018: Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial Respiratory Research 19(1): 237
Busch, R.; Han, M.K.; Bowler, R.P.; Dransfield, M.T.; Wells, J.Michael.; Regan, E.A.; Hersh, C.P.; Crapo, J.; Silverman, E.; Make, B.; Regan, E.; Beaty, T.; Laird, N.; Lange, C.; Cho, M.; Santorico, S.; Hokanson, J.; Hansel, N.; Hersh, C.; Castaldi, P.; McDonald, M-Lynn.; Wan, E.; Hardin, M.; Hetmanski, J.; Parker, M.; Foreman, M.; Hobbs, B.; Busch, R.; El-Boueiz, A.; Castaldi, P.; Hardin, M.; Qiao, D.; Regan, E.; Halper-Stromberg, E.; Begum, F.; Won, S.; Lutz, S.; Lynch, D.A.; Coxson, H.O.; Han, M.K.; Hoffman, E.A.; Humphries, S.; Jacobson 2016: Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort Bmc Pulmonary Medicine 16: 28
Dekhuijzen, P.N.R.; Batsiou, M.; Bjermer, L.; Bosnic-Anticevich, S.; Chrystyn, H.; Papi, A.; Rodríguez-Roisin, R.; Fletcher, M.; Wood, L.; Cifra, A.; Soriano, J.B.; Price, D.B. 2016: Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device Respiratory Medicine 120: 54-63
Mannan, H.; Foo, S.W.; Cochrane, B. 2019: Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? a comparative trial of two devices Bmc Research Notes 12(1): 94
Price, M.; Mahajan, P.; Maden, C.; Thwaites, R. 1997: Parental preference for the Babyhaler inhalation device and its ease of use in the administration of inhaled asthma medication to pre-school children European Respiratory Journal Suppl 10(25): 81S
Thorsson, L.; Geller, D. 2005: Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide Respiratory Medicine 99(7): 836-849
Hendriks, J.J.E.; Overberg, P.C.; Brackel, H.J.L. 1995: Handling study of a new small volume spacer device in 0-3 years old children with signs and symptoms of asthma using regular inhaled medication European Respiratory Journal 8(Suppl 19): 159S
Yeh, W.; Stanford, R.H.; Stempel, D.A. 2008: Use of fluticasone propionate/salmeterol in a single device is associated with higher controller to total asthma medication ratios compared to inhaled corticosteroid therapy Journal of Allergy and Clinical Immunology 121(2, Suppl 1): S10
Karpel, J P.; Kotch, A; Zinny, M; Pesin, J; Alleyne, W 1994: A Comparison of Inhaled Ipratropium, Oral Theophylline Plus Inhaled β-Agonist, and the Combination of All Three in Patients With COPD Chest Journal 105(4): 1089-1094
Wang, M.-T.; Lai, J.-H.; Huang, Y.-L.; Liou, J.-T.; Cheng, S.-H.; Lin, C.W.; Pan, H.-Y.; Hsu, Y.-J.; Tsai, C.-L. 2021: Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD a Propensity Score-Inverse Probability of Treatment Weighting Cohort Study Chest 160(4): 1255-1270
Knox, A.J.; Muers, M.F. 1990: Do inhaled ipratropium or oral theophylline offer benefit over treatment with inhaled beta agonists in copd American Review of Respiratory Disease 141(4 Part 2): A321
Karpel, J.P.; Kotch, A.; Zinny, M.; Pesin, J.; Alleyne, W. 1994: A comparison of inhaled ipratropium, oral theophylline plus inhaled beta-agonist, and the combination of all three in patients with COPD Chest 105(4): 1089-1094
Cheng, S.-L.; Wang, H.H.; Lin, C.-H. 2017: Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD International Journal of Chronic Obstructive Pulmonary Disease 12: 2231-2238
Kardos, P. 2018: Rolle der inhalativen Kortikosteroide bei Copd; The role of inhaled corticosteroids in Copd; Der Pneumologe 15(1): 43-44
Hirai, K.; Tanaka, A.; Homma, T.; Kawahara, T.; Oda, N.; Mikuni, H.; Uchida, Y.; Uno, T.; Miyata, Y.; Inoue, H.; Ohta, S.; Yamaguchi, F.; Suzuki, S.; Sagara, H. 2021: Prevalence and clinical features of asthma-COPD overlap in patients with COPD not using inhaled corticosteroids Allergology International: Official Journal of the Japanese Society of Allergology 70(1): 134-135
Ignatiev, V.A.; Zablotskaia, N.G.; Alcatseva, N.I. 1998: Comparative study of efficacy of combined inhaled bronchodilators and inhaled corticosteroids during 12 weeks therapy in COPD patients European Respiratory Journal 12(Suppl 28): 40S